BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

NCT02672852 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

507

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Risankizumab
DRUG: Placebo

Sponsor

AbbVie

Collaborators

[object Object]